TP 6076

Drug Profile

TP 6076

Alternative Names: TP6076

Latest Information Update: 03 Aug 2016

Price : $50

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Antibacterials; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Bacterial infections (In volunteers) (IV)
  • 09 Apr 2016 Pharmacodynamics data from preclinical trials in Bacterial infections presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top